How BTK Inhibitors Differ From Current CSU Treatment Approaches

Author(s):

Giselle Mosnaim, MD, MS ,Shyam Joshi, MD

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors offer a novel upstream approach, in contrast to current treatments that work downstream by either blocking released mediators (antihistamines), neutralizing circulating IgE (omalizumab), or broadly suppressing immune responses (immunosuppressants).

EP: 1.Chronic Spontaneous Urticaria and Bruton Tyrosine Kinase: A Multispecialty Expert Discussion

EP: 2.Pathophysiology of Chronic Spontaneous Urticaria

EP: 3.Current CSU Treatment Approach and the Role of Bruton Tyrosine Kinase

EP: 4.BTK Inhibition as a Strategy for CSU Treatment

Now Viewing

EP: 5.How BTK Inhibitors Differ From Current CSU Treatment Approaches

Video content above is prompted by the following:

How do BTK inhibitors differ from the current treatment approach for chronic spontaneous urticaria (CSU) (antihistamines, omalizumab, immunosuppressants)?